Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

28.81 -0.19 (-0.66%)

Streaming Delayed Price Updated: 11:34 AM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

A Look Ahead: Stoke Therapeutics's Earnings Forecast ↗

August 11, 2025

Via Benzinga

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

August 11, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

August 11, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

August 07, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts ↗

January 08, 2025

Via Benzinga

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

August 06, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday ↗

July 22, 2025

Via Benzinga

This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 18, 2025

Via Benzinga

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 16, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals ↗

May 29, 2025

STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's...

Via Chartmill

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗

May 01, 2025

The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.

Via Investor's Business Daily

Topics Earnings

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

April 01, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics ↗

March 18, 2025

Via Benzinga

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 18, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces CEO Transition

March 18, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

February 26, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗

February 18, 2025

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Via Benzinga

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

February 18, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

February 18, 2025

From Biogen Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 11, 2025

Via Benzinga

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

January 07, 2025

From Stoke Therapeutics

Via Business Wire

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

January 06, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

December 06, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.